Mineralys Therapeutics (NASDAQ:MLYS) Hits New 1-Year High - Should You Buy?
Mineralys Therapeutics (NASDAQ:MLYS) reached a new 52-week high of $39.50, closing at $39.49 with a trading volume of 337,173 shares. Analysts have issued positive ratings, with HC Wainwright maintaining a "buy" rating and a target price of $42.00, while Goldman Sachs raised their target from $32.00 to $52.00. The company has a market cap of $2.67 billion and reported earnings of ($0.66) per share, beating estimates. Insiders have sold shares recently, and institutional investors hold 84.46% of the stock.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $39.50 and last traded at $39.49, with a volume of 337173 shares. The stock had previously closed at $37.29.
Get Mineralys Therapeutics alerts:
Analyst Ratings Changes
- There's a Lot to Love About Mineralys' Valentine's Day IPO
A number of equities research analysts have recently issued reports on MLYS shares. HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a report on Monday, September 8th. The Goldman Sachs Group upped their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a "buy" rating in a report on Tuesday, September 9th. Wall Street Zen raised shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, August 22nd. Wells Fargo & Company boosted their price target on shares of Mineralys Therapeutics from $26.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, September 11th. Finally, Bank of America upped their target price on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $43.50.
View Our Latest Analysis on MLYS
Mineralys Therapeutics Stock Up 7.8%
The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -11.26 and a beta of -0.29. The company has a fifty day moving average price of $19.30 and a two-hundred day moving average price of $16.03.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.12. On average, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Adam Scott Levy sold 59,925 shares of the stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $14.76, for a total value of $884,493.00. Following the completion of the sale, the chief financial officer directly owned 132,934 shares of the company's stock, valued at approximately $1,962,105.84. This represents a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 15,884 shares of the stock in a transaction that occurred on Friday, July 11th. The shares were sold at an average price of $14.51, for a total value of $230,476.84. Following the completion of the sale, the chief executive officer directly owned 846,405 shares of the company's stock, valued at $12,281,336.55. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 134,418 shares of company stock valued at $2,185,474. 25.56% of the stock is owned by insiders.
Institutional Investors Weigh In On Mineralys Therapeutics
Several hedge funds have recently modified their holdings of MLYS. Northern Trust Corp lifted its holdings in shares of Mineralys Therapeutics by 0.7% during the fourth quarter. Northern Trust Corp now owns 246,113 shares of the company's stock worth $3,030,000 after purchasing an additional 1,688 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth $48,000. Bank of America Corp DE lifted its holdings in shares of Mineralys Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 107,703 shares of the company's stock worth $1,326,000 after purchasing an additional 11,549 shares during the period. Deutsche Bank AG lifted its holdings in shares of Mineralys Therapeutics by 62.3% during the fourth quarter. Deutsche Bank AG now owns 26,732 shares of the company's stock worth $329,000 after purchasing an additional 10,264 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Mineralys Therapeutics by 1,015.8% during the fourth quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock worth $13,562,000 after purchasing an additional 1,002,941 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.
About Mineralys Therapeutics
(Get Free Report)Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Featured Stories
- Five stocks we like better than Mineralys Therapeutics
- Growth Stocks: What They Are, Examples and How to Invest
- The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?
- There Are Different Types of Stock To Invest In
- Bloom Energy Booms on AI Power Demand and Analyst Upgrades
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- New Catalysts Build Positive Pressure on Intel Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Mineralys Therapeutics Right Now?
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
